Loading clinical trials...
Loading clinical trials...
A Randomised, Double-blind, Double-dummy, Active-controlled, Parallel-group Study to Assess and Compare Efficacy and Safety of an 8-week Treatment With BI 54903 at Doses of 90.9, 181.8 and 363.6 µg b.i.d. Administered Via Respimat® Inhaler and Fluticasone Propionate HFA MDI 440 µg b.i.d. in Patients With Asthma Inadequately Controlled on Medium Dose ICS Therapy
Conditions
Interventions
Placebo
Fluticasone propionate
+1 more
Locations
37
United States
1248.7.01047 Boehringer Ingelheim Investigational Site
Fountain Valley, California, United States
1248.7.01023 Boehringer Ingelheim Investigational Site
Fullerton, California, United States
1248.7.01038 Boehringer Ingelheim Investigational Site
Long Beach, California, United States
1248.7.01004 Boehringer Ingelheim Investigational Site
Mission Viejo, California, United States
1248.7.01028 Boehringer Ingelheim Investigational Site
Palmdale, California, United States
1248.7.01044 Boehringer Ingelheim Investigational Site
Stockton, California, United States
Start Date
July 1, 2011
Primary Completion Date
December 1, 2011
Completion Date
December 14, 2011
Last Updated
February 7, 2025
NCT07431021
NCT07383896
NCT07282886
NCT07356310
NCT06003569
NCT05562466
Lead Sponsor
Boehringer Ingelheim
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions